S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.

Bibliographic Details
Main Authors:	Thomas Ernst, Philipp Le Coutre, Martina Crysandt, Tim H Brümmendorf, Georg-Nikolaus Franke, Thomas Illmer, Andreas Burchert, Fabian Lang, Susanne Saussele, Lino Lars Teichmann, Markus Radsak, Stefan Krause, Jenny Rinke, Christian Fabisch, Thomas Lang, Markus Pfirrmann, Andreas Hochhaus
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967536.34543.a6

Similar Items

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
by: Andreas Hochhaus, et al.
Published: (2023-08-01)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
by: Andreas Hochhaus, et al.
Published: (2023-08-01)

P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL
by: Philipp Le Coutre, et al.
Published: (2023-08-01)

Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
by: Sandeep Padala, et al.
Published: (2023-04-01)

S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE
by: D. Rea, et al.
Published: (2022-06-01)

P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL
by: T. Hughes, et al.
Published: (2022-06-01)

Safety and Efficacy of Asciminib in Chronic Myeloid Leukemia Patient with Chronic Kidney Diseases: A Case Report
by: Awni Alshurafa, et al.
Published: (2024-01-01)

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia
by: Thoralf Lange, et al.
Published: (2013-05-01)

P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY
by: Timothy Hughes, et al.
Published: (2023-08-01)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
by: T. Hughes, et al.
Published: (2022-06-01)

Immune targeting of chronic myeloid leukemia to improve treatment outcome
by: Andreas Burchert
Published: (2018-06-01)

S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
by: Nikola Čuřík, et al.
Published: (2023-08-01)

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.
by: Elena Kuzmina, et al.
Published: (2023-08-01)

PB2478: ASCIMINIB INDUCES ERYTHROPOIESIS IN CHRONIC MYELOID LEUKEMIA CELLS THROUGH DIFFERENTIATION AND NOT BY SELECTION
by: Hammad Hassan, et al.
Published: (2023-08-01)

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes
by: Hijiya N, et al.
Published: (2023-08-01)

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib
by: Thomas Ernst, et al.
Published: (2009-09-01)

Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
by: Camille C.B. Kockerols, et al.
Published: (2022-09-01)

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
by: Seiichi Okabe, et al.
Published: (2023-09-01)

PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS
by: M. Breccia, et al.
Published: (2022-06-01)

P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION
by: Massimo Breccia, et al.
Published: (2023-08-01)

HAIR REPIGMENTATION IN AN OLDER PATIENT TREATED WITH ASCIMINIB
by: Burcu Altındağ Avcı, et al.
Published: (2024-12-01)

Grippers in motion : the fascination of automated handling tasks /
by: 441543 Wolf, Andreas, et al.
Published: (2005)

Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
by: Valentin Garcia-Gutierrez, et al.
Published: (2024-11-01)

P681: MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA
by: Ehab Atallah, et al.
Published: (2023-08-01)

Treatment of chronic myeloid leukemia in blast crisis
by: R. Hehlmann, et al.
Published: (2008-12-01)

The fascination of numbers /
by: 184064 Reichmann, William John
Published: (1957)

The fascinating numbers
by: Mohd Atan, Kamel Ariffin
Published: (1996)

This fascinating astronomy /
by: 307816 Komarov, V., et al.
Published: (1976)

The fascination of groups /
by: 346370 Budden, F. J.
Published: (1972)

The fascinating numbers /
by: 190827 Kamel Ariffin Mohd. Atan
Published: (1996)

P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE
by: A. Innes, et al.
Published: (2022-06-01)

Grippers in Motion : The Fascination of Automated Handling Tasks /
by: Wolf, Andreas, author 441543, et al.
Published: (2019)

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
by: Christian Michel, et al.
Published: (2019-05-01)

P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES
by: Fabian Lang, et al.
Published: (2023-08-01)

P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA
by: Aram Bidikian, et al.
Published: (2023-08-01)

P718: ASCIMINIB MANAGED-ACCESS PROGRAM (MAP) IN RUSSIA
by: O. Shukhov, et al.
Published: (2022-06-01)

EZH2 in Myeloid Malignancies
by: Jenny Rinke, et al.
Published: (2020-07-01)

Unmasking fascinating fungi
by: Saad, Wan Zuhainis
Published: (2014)

The fascinating world of flukes
by: Mohd. Shaharom, Faizah
Published: (2002)

Comment on “Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed” Haematologica 2011;96(12):1779–82
by: Michael Lauseker, et al.
Published: (2012-05-01)